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Summary
Dexras1 is a 30 kDa G protein in the Ras subfamily
whose discovery was based on its pronounced induc-
ibility by the glucocorticoid dexamethasone. It binds
to neuronal nitric oxide synthase (nNOS) via the adap-
tor protein CAPON, eliciting S-nitrosylation and acti-
vation of Dexras1. We report that Dexras1 binds to the
peripheral benzodiazepine receptor-associated pro-
tein (PAP7), a protein of unknown function that binds
to cyclic AMP-dependent protein kinase and the pe-
ripheral benzodiazepine receptor. PAP7 in turn binds
to the divalent metal transporter (DMT1), an iron im-
port channel. We have identified a signaling cascade
in neurons whereby stimulation of NMDA receptors
activates nNOS, leading to S-nitrosylation and activa-
tion of Dexras1, which, via PAP7 andDMT1, physiolog-
ically induces iron uptake. As selective iron chelation
prevents NMDA neurotoxicity in cortical cultures, the
NMDA-NO-Dexras1-PAP7-DMT1-iron uptake signaling
cascade also appears to mediate NMDA neurotoxicity.
Introduction
It is increasingly appreciated that nitric oxide (NO) may
not simply diffuse freely to reach its physiological tar-
gets but may be conveyed to these sites by interactions
of NO synthase (NOS) with other proteins. One of the
best known examples involves neuronal NOS (nNOS)
binding to the adaptor protein PSD-95/93, which in
turn binds to NMDA receptors (Brenman et al., 1996a,
1996b). This ternary complex enables NO to S-nitrosy-
late NMDA receptors and alters their signaling (Lipton
et al., 1993). Earlier, we identified CAPON, a 55 kDa pro-
tein that contains a C-terminal domain that binds to the
PDZ domain of nNOS as well as an N-terminal phospho-
tyrosine binding (PTB) domain (Jaffrey et al., 1998).
CAPON interacts with Dexras1, a brain-enriched mem-
ber of the Ras family of small G proteins that is selec-
tively induced by dexamethasone (Fang et al., 2000;
Kemppainen and Behrend, 1998). Dexras1 shares about
35% homology with the Ras subfamily of proteins and
*Correspondence: ssnyder@jhmi.edu
5 These authors contributed equally to this work.contains all of the conserved domains of typical
GTPases, such as the GTP binding domain, the Mg2+
binding domain, and a C-terminal prenylation site.
Unlike conventional GTPases, Dexras1 contains an
extended 7 kDa C-terminal tail. Dexras1 has also been
designated activator of g protein signaling 1 (AGS1) or
RASD1 (Blumer et al., 2005). The term "AGS1" refers to
the ability of Dexras1 to selectively bind to Gai2, increas-
ing GTPgS binding to Gi and Go and activating extracel-
lular signal-regulated kinases 1,2 (ERK1,2) (Cismowski
et al., 2000, 2001; Graham et al., 2002).
NMDA receptor stimulation of nNOS activates Dex-
ras1. Glutamate via NMDA receptors triggers cellular
calcium entry with calcium-calmodulin activating nNOS
(Bredt and Snyder, 1994), whose binding to CAPON pro-
vides a mechanism for NO delivery to Dexras1, leading to
S-nitrosylation of Dexras1 on cysteine-11 (Fang et al.,
2000; Jaffrey et al., 1998, 2002). The selective lessening
of Dexras1 activation in the brains of mice with targeted
deletion of nNOS and the existence of a ternary complex
of nNOS, CAPON, and Dexras1 establish that neuronally
derived NO physiologically serves as a guanine nucleo-
tide exchange factor to activate Dexras1 by S-nitrosyla-
tion (Fang et al., 2000).
Thus far, the physiological function of S-nitrosylated
Dexras1 has not been determined. In the present study,
to characterize downstream targets of Dexras1, we have
conducted yeast two-hybrid analysis and discovered
interactions of Dexras1 with PAP7, a protein which was
discovered on the basis of its binding to peripheral ben-
zodiazepine receptors and cAMP-dependent protein
kinase (Li et al., 2001). We demonstrate that PAP7 binds
to DMT1, the only known physiological import channel
for iron. We show that activation of glutamate-NMDA
receptors stimulates nNOS, resulting in S-nitrosylation
and activation of Dexras1, which physiologically induces
iron uptake via interactions with PAP7 and DMT1. This
signaling cascade participates in NMDA neurotoxicity
that is prevented by selective iron chelation.
Results
Dexras1, PAP7, and DMT1 Physiologically Interact
To elucidate physiologic roles for Dexras1, we con-
ducted yeast two-hybrid analysis utilizing full-length
Dexras1 fused to the GAL4 DNA binding domain, and a
rat whole-brain cDNA library fused to the GAL4 DNA
activation domain. A single colony identified PAP7 as a
potential interactor (data not shown). PAP7 is a 62 kDa
protein and includes several domains: an acyl-coenzy-
meA binding protein signature and a bipartite nuclear lo-
calization signal at the N terminus, a Golgi dynamics
(GOLD) domain at the C terminus, and a glutamate(E)-,
glutamine(Q)- and an asparagine(N)-rich region in the
middle of the protein (Li et al., 2001) (Figure 1A). Western
blot analysis reveals substantial levels of PAP7 in multi-
ple mouse tissues, including brain, adrenal, heart, lung,
liver, spleen, and testes, but no detectable protein in the
kidney, whereas Dexras1 is brain selective with modest
levels in heart and testes (Figure 1B). PAP7 is expressed
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432Figure 1. Characterization of PAP7
(A) Schematic diagram of PAP7. An Acyl-CoA
binding protein domain (ACBP) and bipartite
nuclear localization signal (NLS) are located
at the N terminus, while a Golgi dynamics
(GOLD) domain resides at the C terminus.
The middle of the protein contains aspara-
gine (N)-, glutamate (E)-, and glutamine (Q)-
rich domains. The Dexras1 binding domain
is located between amino acids 193–444 as
determined by yeast two-hybrid analysis.
(B) PAP7 occurs in all major tissues, except
kidney, while nNOS is brain specific, and
Dexras1 is predominantly in the brain, with
moderate levels in the heart and testis.
(C) PAP7 is present at similar levels in differ-
ent regions of the brain.
(D) Dexras1 and PAP7 are present in high
levels in PC12 cells, with small levels in
HEK293T cells.
(E) Undifferentiated PC12 cells were trans-
fected with a Golgi marker and stained for
endogenous PAP7, revealing that PAP7 is lo-
calized to both the Golgi apparatus and the
cytosol.at similar levels in several areas of the brain (Figure 1C).
Both PAP7 and Dexras1 occur in high levels in undiffer-
entiated PC12 cells, with very low levels in HEK293T
cells (Figure 1D).
We have confirmed the Dexras1-PAP7 interaction by
transient transfection of GST-PAP7 and Dexras1-Myc
in HEK293T cells, which reveals selective binding of
Dexras1 and PAP7 (Figure 2A). PAP7 also binds to a con-
stitutively active form of Dexras1 (A178V) (Graham et al.,
2001) at about the same level as wild-type, indicating
that the activity status of Dexras1 is not important for
protein interaction. Yeast two-hybrid analysis suggests
that Dexras1 interacts with PAP7 between amino acids
193–444, encompassing parts of the E-, Q-, and N-rich
domains as well as the first part of the GOLD domain.
To confirm the importance of PAP7-193–444 for Dexras1
binding, we conducted immunoprecipitation experi-
ments in HEK293 cells containing overexpressed PAP7
and Dexras1 and observe coprecipitation of PAP7-
193–444 with Dexras1 of comparable magnitude to the
coprecipitation of wild-type PAP7 and Dexras1 (Fig-
ure 2B). To evaluate the interaction of endogenous Dex-
ras1, PAP7, and DMT1, we first employed PC12 cells
that contain high levels of both PAP7 and Dexras1. Uti-
lizing an antibody to Dexras1, we observe coimmuno-
precipitation with PAP7 (Figure 2C).
An NCBI nucleotide sequence submission reported
PAP7 as interacting with DMT1 (NCBI accession number
NM_182843). DMT1, a twelve-transmembrane channel
localized to the plasma membrane, is the only known
mammalian iron transporter associated with iron import
into cells. It was previously identified as natural resis-
tance-associated macrophage protein-2 (Nramp2) anddivalent cation transporter (DCT1) (Cellier et al., 1995;
Fleming et al., 1997). Using an antibody to DMT1, we
have confirmed the binding of PAP7 and DMT1 by coim-
munoprecipitation in PC12 cells (Figure 2D). To examine
a more physiologic preparation, we conducted immuno-
precipitation experiments in whole mouse brain and
examined for the presence of a ternary complex (Fig-
ure 2E). Utilizing an antibody to PAP7, we observe simul-
taneous coprecipitation with DMT1 and Dexras1. Thus,
these three proteins appear to exist in a ternary complex
in intact brain, suggesting that they may interact physi-
ologically. Immunohistochemical staining of undifferen-
tiated PC12 cells reveals that PAP7 is localized to the
Golgi apparatus (Figure 1E) and to the cytosol, while
Dexras1 is cytosolic and plasma membrane associated
(Figure 2C). Localization of PAP7 in Golgi, where it inter-
acts with gigantin and was designated GCP60, has been
previously reported (Sohda et al., 2001).
Iron Uptake Is Regulated by Dexras1-PAP7-DMT1
Interactions
Iron is transported into cells as either transferrin (Tf)-iron
or non-transferrin bound iron (NTBI) (Hentze et al., 2004;
Richardson and Ponka, 1997). Iron required for physio-
logical processes, such as synthesis of heme, enters
cells via the classical Tf-mediated iron uptake pathway
wherein two molecules of diferric iron bind to Tf, which
then binds to the transferrin receptor (TfR). Receptor-
mediated endocytosis leads to internalization of TfR
and DMT1 within an endocytic vesicle containing difer-
ric-Tf. Acidification of the endosome leads to the libera-
tion of iron from Tf, which then exits the endosome
via DMT1 and enters the intracellular labile pool or
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433Figure 2. Dexras1, PAP7, and DMT1 Physio-
logically Interact
(A) HEK293T cells were transfected either
with GST or GST-PAP7 and a Myc-tagged
Dexras1 construct. A178V is a constitutively
active form of Dexras1. Dexras1 and A178V
specifically interact with PAP7.
(B) HEK293T cells were transfected either
with GST or GST-PAP7 or GST-PAP7-193–
444 and a Myc-tagged Dexras1 construct,
showing that Dexras1 is able to bind to
PAP7-193–444, as originally shown by yeast
two-hybrid analysis.
(C) Immunoprecipitation experiments were
performed using undifferentiated PC12 cells
with a Dexras1 antibody, showing coprecipi-
tation of PAP7.
(D) Immunoprecipitation experiments were
performed using undifferentiated PC12 cells
with a DMT1 antibody, showing coprecipita-
tion of PAP7.
(E) Immunoprecipitation experiments were
performed using mouse brain lysate with a
PAP7 antibody, showing simultaneous im-
munoprecipitation of Dexras1 and DMT1.
(F) Undifferentiated PC12 cells were fixed and
stained for endogenous Dexras1 and PAP7.
Dexras1 is shown to be localized to the cyto-
sol and plasma membrane, while PAP7 is
localized to the cytosol and Golgi apparatus.mitochondria for heme biosynthesis (Picard et al., 2000).
For NTBI uptake, DMT1 in the plasma membrane di-
rectly mediates iron import (Farcich and Morgan, 1992;
Garrick et al., 1999; Richardson and Ponka, 1997). In
the brain, the extracellular iron concentration exceeds
that of serum transferrin, so that both Tf-mediated and
NTBI uptake pathways import iron (Moos and Morgan,
1998; Rouault, 2001).
Since PAP7 binds to DMT1, we wondered whether
Dexras1 and PAP7 influence iron homeostasis. In
HEK293T cells, overexpression of Dexras1 very mod-
estly augments both NTBI (Figure 3A) and Tf-associated
(data not shown) iron uptake, which is substantially en-
hanced by cotransfection with PAP7. Thus, PAP7 is re-
quired for a robust influence of Dexras1 on iron uptake.
The action of Dexras1 on iron uptake derives from its
GTPase actions, as constitutively active Dexras1, with
a mutation of alanine-178 to valine (A178V), increases
iron uptake more than native Dexras1 in the presence
or absence of PAP7 (Figure 3A).
As NO S-nitrosylates and activates Dexras1 (Fang
et al., 2000), we examined effects of NO donors on iron
uptake. Treatment of undifferentiated PC12 cells with
S-nitrosoglutathione (GSNO) results in S-nitrosylation
of Dexras1 (Figure 3B) and enhances NTBI uptake (Fig-
ure 3C). Other NO donors, sodium nitroprusside (SNP)
(Figure 3D) and DETANONOate (Figure 3E), elicit similar
effects. As Dexras1 activation byS-nitrosylation involves
cysteine-11 (Jaffrey et al., 2002), we examined effects ofa Dexras1 cysteine mutant (C11S) on NO-mediated iron
uptake. The C11S mutant still interacts with PAP7
(Figure 4A); however, in HEK293T cells transfected
with PAP7 and wild-type or C11S-mutated Dexras1,
the C11S mutation abolishes GSNO activation of NTBI
uptake (Figure 4B).
To determine whether Dexras1 is required for NO-me-
diated iron uptake, we sought to deplete Dexras1. Since
it is difficult to transfect primary cortical neurons, we
employed undifferentiated PC12 cells, which contain
endogenous Dexras1, PAP7, and DMT1. We success-
fully depleted Dexras1 in PC12 cells using RNA interfer-
ence (Figure 4C). While GSNO augments NTBI uptake in
control PC12 cells, it fails to increase uptake in the Dex-
ras1-depleted cells (Figure 4D).
Since Dexras1 is activated by glutamate-NMDA neu-
rotransmission acting via NO, we examined the influ-
ence of NMDA upon iron uptake in primary cortical neu-
ronal cultures. NMDA treatment increases iron uptake in
a concentration-dependent manner (Figure 5A), with the
effects blocked by pretreatment with the NMDA antago-
nist MK801 (Figure 5C). NMDA fails to increase NTBI up-
take in cultures from nNOS knockout mice (Figures 5B
and 5C), showing that nNOS and NO are required for
NMDA-mediated NTBI uptake. NMDA transmission aug-
ments calcium conductance, which fits with the ability of
the calcium ionophore, ionomycin, to stimulate NTBI up-
take, an effect abolished in nNOS knockout cultures
(Figure 5B).
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434Figure 3. Dexras1 Is S-Nitrosylated and NTBI
Uptake Is Increased in PC12 Cells after Treat-
ment with NO Donors
(A) HEK293T cells were transfected with Dex-
ras1 or Dexras1-A178V in the presence or ab-
sence of PAP7. NTBI uptake was measured
as described in the Experimental Procedures.
(*p < 0.05, **p < 0.01). (B) Dexras1 in undiffer-
entiated PC12 cells is S-nitrosylated by
GSNO in a concentration-dependent manner.
(C) GSNO treatment for 3 hr leads to a con-
centration-dependent increase NTBI uptake
in undifferentiated PC12 cells, as does (D)
SNP for 1 hr and (E) DETA NONOate for 4 hr.
(All NTBI uptake experiments were repeated
three times, each sample in triplicate. Com-
parison with two-tailed Student’s t test; error
bars represent SEM.)Physiological and Pathophysiological Relevance
of Dexras1 Regulation of Iron Uptake
Tf-mediated iron uptake is also augmented by treatment
with NMDA (Figure 6A) or ionomycin (Figure 6B), effects
abolished by pretreatment with MK801(+) (Figure 6C) or
in nNOS knockout cultures (Figures 6B and 6C). To as-
sess the physiological relevance of NMDA-stimulated
iron uptake, we monitored 55Fe incorporation into
heme in cortical cultures treated with NMDA (Figure 7A).
NMDA stimulation markedly increases the rate of heme
biosynthesis.
We wondered whether the stimulation of iron uptake
by NMDA neurotransmission might have pathophysio-
logic consequences, as overactivation of NMDA recep-
tors leads to neurotoxicity, which has been implicated
in vascular stroke and neurodegenerative diseases
(Choi, 1994). In cerebrocortical cultures, a concentration
of 300 mM NMDA is well established to elicit neurotoxic-
ity (Dawson et al., 1991; Koh and Choi, 1988). We have
verified that this concentration of NMDA elicits a major
augmentation of iron uptake (Figure 7B). As neurotoxic-
ity is associated with a pronounced increase in reactive
oxygen species (ROS), we monitored ROS formation
utilizing a dye that selectively detects hydroxyl free rad-
icals. These predominantly arise from the Fenton reac-
tion that typically reflects iron interacting with hydrogen
peroxide to form hydroxyl free radicals. Treatment with
300 mM NMDA elicits a 3.5-fold augmentation in hy-
droxyl free radical formation (Figure 7C). To determinewhether this increase is caused by the Fenton reaction
elicited by iron, we employed salicylaldehyde isonicoti-
noyl hydrazone (SIH), a selective cell-permeable iron
chelator. SIH treatment abolishes the increase in hy-
droxyl free radicals caused by NMDA (Figure 7C), imply-
ing that the free radical formation arises from iron whose
influx is stimulated by NMDA. To ascertain whether the
prevention of free radical formation by SIH also prevents
neurotoxocity, we measured neurotoxicity in the same
cortical cultures utilizing propidium iodide staining to
monitor dead cells (Figure 7D). In these preparations,
300 mM NMDA kills more than 90% of cells, while pre-
treatment with the NMDA antagonist MK801 (10 mM)
provides virtually complete protection. Pretreatment
with 100 mM SIH also markedly protects the neurons
from cell death. Thus, it appears that iron contributes
both to the NMDA-elicited formation of free radicals
and neuronal death.
Discussion
In the present study, we have identified a signaling cas-
cade whereby neurotransmission regulates iron homeo-
stasis (Figure 8). Glutamate, acting via NMDA receptors,
activates nNOS to form NO (Bredt and Snyder, 1994),
which leads to protein S-nitrosylation (Hess et al.,
2005). This modification activates Dexras1, which, by
its link to PAP7, augments both Tf-mediated and NTBI
uptake. PAP7 does not appear to have a direct influence
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ated by S-Nitrosylation of Dexras1
(A) HEK293T cells were transfected with GST
orGST-PAP7Dexras1-C11S-myc, anitrosyla-
tion-dead mutant which is able to bind specif-
ically to PAP7.
(B) HEK293T cells were transfected with
PAP7 and either wild-type Dexras1 or the
C11S mutant. After transfection, the cells
were treated with 100 mM GSNO for 3 hr and
NTBI uptake was measured (*p < 0.01). GSNO
treatment upregulates NTBI uptake in cells
containing wild-type Dexras1, but not the
C11S mutant.
(C) Undifferentiated PC12 cells were trans-
fected with either control RNAi or Dexras1
RNAi (mock is untransfected). Dexras1 pro-
tein levels was fully depleted after transfec-
tion with Dexras1 RNAi, but not in control or
mock-transfected cells.
(D) Undifferentiated PC12 cells were trans-
fected with either control RNAi or Dexras1
RNAi, treated with 100 mM GSNO for 3 hr,
and NTBI uptake was measured (*p < 0.01).
GSNO treatment upregulates NTBI uptake in
control cells, but not in cells depleted of Dex-
ras1.
(All NTBI uptake experiments were repeated
three times, each sample in triplicate. Com-
parison with two-tailed Student’s t test; error
bars represent SEM.)on iron homeostasis, as its overexpression does not
affect iron uptake, though it does potentiate Dexras1-in-
duced enhancement of iron uptake. Instead, it presum-
ably serves as a scaffold bringing Dexras1 into proximity
to DMT1. Stimulation of iron uptake by Dexras1 reflects
its GTPase activity, as constitutively active Dexras1
manifests enhanced activity in stimulating iron uptake.The influence of Dexras1 upon iron uptake is evidently
the first example of a G protein regulating an iron trans-
porter.
Besides the role of the NMDA-NO-Dexras1-PAP7-
DMT1 cascade in mediating physiologic influences of
NMDA on iron uptake, our findings implicate this path-
way in pathophysiologic actions of NMDA-glutamateFigure 5. Glutamate-NMDA Neurotransmis-
sion Increases NTBI Uptake, which Is Abol-
ished in nNOS Knockout Mice
(A) NMDA stimulation increases NTBI uptake
in primary cortical neurons in a concentra-
tion-dependent manner. (B) NTBI uptake in
primary cortical neurons is increased by
both NMDA stimulation and ionomycin treat-
ment, a calcium ionophore. This upregulation
is not seen in primary cortical neurons from
nNOS knockout mice (*p < 0.05, **p < 0.01)
and (C) is abolished by pretreatment with
MK801, an NMDA receptor antagonist (*p <
0.005). (All NTBI uptake experiments were
repeated three times, each sample in tripli-
cate. Comparison with two-tailed Student’s
t test; error bars represent SEM.)
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436Figure 6. Glutamate-NMDA Neurotransmis-
sion Increases Tf-Iron Uptake, which Is Abol-
ished in nNOS Knockout Mice
(A) Tf-mediated iron uptake is increased in
a dose-dependent manner with NMDA treat-
ment in primary cortical neurons. (B) Tf-medi-
ated iron uptake is increased by both NMDA
and ionomycin (*p < 0.01, **p < 0.01). This up-
regulation is not seen in primary cortical neu-
rons from nNOS knockout mice and (C) is
abolished by pretreatment with MK801 (*p <
0.005). No increase in uptake is seen in neu-
rons from nNOS knockout mice. (All Tf uptake
experiments were repeated three times, each
sample in triplicate. Comparison with two-
tailed Student’s t test; error bars represent
SEM.)neurotransmission. Thus, excessive NMDA receptor
activation is thought to mediate the neurotoxicity that
occurs in vascular stroke and other neurodegenerative
conditions (Choi, 1994). While such neurotoxicity may
involve multiple systems activated by the calcium entry
associated with NMDA transmission, NO formation has
been implicated. Inhibitors of NOS prevent NMDA neu-
rotoxicity and stroke damage, while neurotoxicity and
stroke damage are markedly reduced in brains of
nNOS2/2 mice (Huang et al., 1994). In our experiments,
selective chelation of intracellular iron blocks formation
of free radicals in brain cultures and also markedly atten-
uates NMDA neurotoxicity. This implies that iron uptake
in response to NMDA-NO activation plays an important
role in neurotoxicity.
The molecular mechanism whereby Dexras1 and its
GTPase activity regulate signaling via PAP7 and DMT1
is unclear. We presume that Dexras1 influences DMT1
directly but cannot rule out some action upon PAP7.
Conceivably, other reported activities of Dexras1 may
participate. For instance, Dexras1 activates the ERK1,2
pathway in a pertussis toxin-sensitive fashion (Cismow-
ski et al., 2000). It impairs activation of G protein-coupled
receptors that act via Gi, inhibiting adenylyl cylase (Gra-
ham et al., 2004; Nguyen and Watts, 2005). Functional
relevance of those effects is suggested by its involve-
ment in regulating circadian rhythm. Dexras1 expression
cycles in a circadian fashion in the suprachiasmatic
nucleus (Takahashi et al., 2003). Its genetic deletion
reduces photic entrainment of circadian responses to
glutamate-NMDA transmission (Cheng et al., 2004).
Interestingly, two spontaneous mutations of DMT1
have been reported in the Belgrade (b/b) rat and micro-
cytic anemia (mk) mice (Fleming et al., 1997, 1998). Sur-
prisingly, both of these spontaneous mutations involved
the same amino acid, glycine 185, which is mutated toarginine. While both mutant rodents display systemic
iron deficiency and anemia, they do survive. This implies
that the G185R mutation confers some selective advan-
tage that may reflect a new constitutive calcium perme-
ability as reported by Xu et al. (Xu et al., 2004).
A homolog of Dexras1 called Ras homolog enriched in
striatum (Rhes, Dexras2) is induced by thyroid hormone,
an interesting contrast to the stimulation of Dexras1 by
glucocorticoids (Falk et al., 1999; Vargiu et al., 2001).
Rhes is selectively localized to the corpus striatum. It
also binds to PAP7 (data not shown) and so might im-
pact NMDA receptor influences on iron entry into the
striatal neurons.
Iron is required for many physiological processes,
such as heme synthesis, mitochondrial oxidation reac-
tions, and DNA synthesis, but is toxic in excess, so
that its cellular disposition is tightly regulated (Hentze
et al., 2004; Richardson and Ponka, 1997). Studies of
iron in the brain have largely focused on its pathophys-
iological roles, with iron accumulation occurring in
numerous neurodegenerative diseases (Ponka, 2004;
Rouault, 2001; Shoham and Youdim, 2000; Zecca
et al., 2004). Heretofore, no influence of neurotransmis-
sion upon iron uptake has been reported. Our findings
establish a physiologic role for glutamate neurotrans-
mission in regulating iron uptake in the brain in a novel
signaling cascade. It is conceivable that misregulation
of this physiological pathway participates in the iron
accumulation in neurodegenerative disease.
Experimental Procedures
Cells and Reagents
HEK293T cells were maintained in DMEM with 10% fetal bovine se-
rum (FBS), 2 mM L-glutamine, and 100 U/ml penicillin-streptomycin
(PS) at 37C with 5% CO2 atmosphere in a humidified incubator.
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serum, 2 mM L-glutamine, and 100 U/ml PS in the same environ-
ment. All chemicals were purchased from Sigma, unless otherwise
indicated.
Generation of Constructs
Rat PAP7 was cloned from EST #5621578 (Open Biosystems) into ei-
ther pCMV-GST or pCMV-HA (Clontech). Rat Dexras1, wild-type and
A178V or C11S mutants, were all cloned into pCMV-Myc (Clontech).
Characterization of PAP7
To examine the expression pattern of PAP7 throughout the body,
a male C57/B6 mouse was dissected, and each organ was homog-
enized in Buffer A (100 mM Tris [pH 7.4], 150 mM NaCl, 1% Triton
X-100, 15% glycerol, 1 mM PMSF, 25 mg/ml antipain, 50 mg/ml
leupeptin, 50 mg/ml aprotinin, 25 mg/ml chymostatin, and 25 mg/ml
pepstatin). Total protein (100 mg) was loaded onto a Western blot
and immunoblotted with a rabbit anti-nNOS antibody (previously
generated in our laboratory), rabbit anti-PAP7 (V. Papadopolous) an-
tibody, and rabbit anti-Dexras1 antibody (Calbiochem).
To examine the expression pattern of PAP7 in the brain, a male
Sprague-Dawley rat brain was dissected into several parts, lysed
in Buffer A, and total protein (100 mg) loaded and a Western blot per-
formed.
To examine the expression pattern of PAP7 and Dexras1 in differ-
ent cell lines, 100 mg of total protein from HEK293T and undifferenti-
ated PC12 cells lysed in Buffer A were loaded onto a Western blot.
GST Pull-Down Assay
GST or GST-tagged PAP7 constructs were cotransfected with Dex-
ras1-Myc constructs into HEK293T cells using PolyFect (Qiagen),
with a transfection efficiency of greater than 90%. Cells were lysed
48 hr after transfection in Buffer A. Lysates were precleared with
Figure 7. Physiological and Pathophysiological Relevance of Iron
Uptake
(A) Rate of heme biosynthesis was measured using incorporation of
55Fe into heme and was increased after NMDA treatment (*p < 0.01).
(B) NTBI uptake is significantly increased after treatment with an ex-
citotoxic concentration of NMDA.
(C) An increase in HPF fluorescence was observed after treatment
with NMDA, indicating an increase in ROS formation. This increase
was abolished with pretreatment of the neurons with SIH.
(D) Treatment of primary cortical neurons with 300 mM NMDA elicits
a high level of neurotoxicity, which is attenuated by the pretreatment
with either 10 mM MK801, an NMDA receptor antagonist, or SIH, an
iron chelator.
(All experiments were repeated three times, each sample in triplicate.
Comparison with two-tailed Student’s t test; error bars represent
SEM.)pansorbin cells (Calbiochem), then 1 mg of total protein was incu-
bated with glutathione-Sepharose beads overnight at 4C. Beads
were washed with Wash Buffer (50 mM Tris [pH 7.4], 500 mM
NaCl, 10 mM b-glycerophosphate) twice, then once with Buffer A.
Beads were quenched in sample buffer (100 mM Tris [pH 6.8],
10% glycerol, 250 mM b-mercaptoethanol, 2% sodium dodecyl sul-
fate, and bromophenol blue). Total protein (50 mg) was loaded as
input. Dexras1-Myc binding was examined using an anti-myc anti-
body (Roche) followed by incubation with anti-mouse secondary
conjugated to horseradish peroxidase(HRP) (Jackson Immunore-
search); blots were then stripped and probed with an anti-GST anti-
body conjugated to HRP to detect PAP7. Chemiluminescence
(Pierce) was used to detect bands on the Western blot.
Coimmunoprecipitation
Undifferentiated PC12 cells were lysed in Buffer A, and lysates were
precleared with protein A Sepharose. 1 mg of total protein was incu-
bated with 2 mg of either goat anti-Dexras1 antibody (Abcam) or
rabbit anti-NRAMP2 antibody (Alpha Diagnostics) overnight at
4C, then protein A Sepharose beads were added for 1 hr. Beads
were washed in Buffer A three times and quenched in sample buffer.
Total PC12 lysate (100 mg) was loaded as input. PAP7 binding was
detected using a rabbit anti-PAP7 antibody, followed by anti-rabbit
Ig conjugated to HRP.
For the ternary complex interaction, a male C57/B6 mouse was
sacrificed, and the whole brain was dissected and homogenized in
Buffer A. Lysates were precleared with protein A Sepharose. 1 mg
of total protein was incubated with 2 mg of rabbit anti-PAP7 antibody
overnight at 4C, then protein A Sepharose beads were added for
1 hr. Beads were washed in Buffer A three times and quenched in
sample buffer. Total brain lysate (100 mg) was loaded as input. Dex-
ras1 and DMT1 binding was detected using a rabbit anti-Dexras1 or
anti-nRAMP2 antibody, followed by anti-rabbit Ig conjugated to
HRP.
Immunofluorescence Staining
Undifferentiated PC12 cells were plated on poly-D-lysine-coated
glass coverslip dishes. For PAP7 localization to the Golgi, these cells
were transfected with a plasmid containing a Golgi marker
Figure 8. Dexras1, PAP7, and DMT1 Mediate Both NTBI and Tf-
Mediated Iron Uptake
A model of a signaling cascade whereby glutamate-NMDA neuro-
transmission regulates cellular iron homeostasis. Glutamate-NMDA
stimulation leads to the activation of nNOS and, via the scaffolding
protein CAPON, to S-nitrosylation of Dexras1, which interacts with
PAP7 and DMT1 both at the endosome and the plasma membrane,
thus influencing cellular iron uptake in the cell.
Neuron
438conjugated to YFP (pEYFP-Golgi, Clonetech) using Lipofectamine
2000 (Invitrogen). After 48 hr, cells were stained as below.
Cells were fixed in 4% paraformaldehyde in PBS, permeabilized
in 1% Triton X-100 in PBS, and blocked in PBS with 1% normal
goat serum and 2% normal horse serum. Endogenous Dexras1
was detected using a goat anti-Dexras1 antibody; endogenous
PAP7 was detected using a rabbit anti-PAP7 antibody. Anti-goat
Ig conjugated to FITC and anti-rabbit Ig conjugated to rhodamine
was obtained from Molecular Probes. Confocal microscropy images
were obtained using a PerkinElmer UltraView LCI (Live Cell Imaging)
System.
S-Nitrosylation of Dexras1
PC12 cells were treated with various concentrations of GSNO (Alexis
Biochemicals) for 3 hr. Cells were washed in PBS and harvested.
S-nitrosylation of Dexras1 was monitored using the biotin-switch
assay previously described (Jaffrey and Snyder, 2001). Dexras1




NTBI uptake assays were performed as previously described (Pic-
ard et al., 2000). In brief, HEK293T cells were transfected (greater
than 90% efficiency) with PAP7-HA and Dexras1-Myc (or mutants)
using Lipofectamine and PLUS Reagent (Invitrogen) for 3 hr in
DMEM only, then supplemented with full media. After 48 hr, the cells
were washed with phosphate-buffered saline (PBS) then resus-
pended into Iron Uptake Buffer (25 mM Tris, 25 mM MES, 140 mM
NaCl, 5.4 mM KCl, 5 mM glucose, 1.8 mM CaCl2 [pH 5.5]) and trans-
ferred to glass test tubes. Ascorbic acid was added to 1 mM FeSO4
at a 44:1 ratio. 55FeCl3 (PerkinElmer Life Science) was added to the
iron/ascorbic acid mixture, which was then added to the cells in Iron
Uptake Buffer to a final concentration of 20 mM. Cells were incubated
at 37C with shaking for 30 min. The cells were washed twice with
cold PBS plus 0.5 mM EDTA and harvested. An aliquot of resus-
pended cells was taken for protein assay using the Bio-Rad Protein
Assay Reagent; the protein concentrations of individual samples
were used to quantitate 55Fe incorporation (cpm/mg protein). Sam-
ples were normalized to control.
Primary Cortical Neurons
Cells were dissected out of E16–E18 wild-type or nNOS knockout
mice and plated in 6-well plates at 3 3 106 cells per well. Cells
were maintained in Primary Neuron Media (Neurobasal media sup-
plemented with B27 serum, 2 mM L-glutamine, and 100 U/ml PS)
at 37C with 5% CO2 atmosphere in a humidified incubator. Using
this media, the growth of the glia is suppressed, and the amount
of glia is less than 0.5% of the total culture, giving us an essentially
pure neuronal culture. Because Mg2+ can block NMDA receptors, we
measured the free Mg2+ levels of the Primary Neuron Media using
a fluorescent Mg2+ indicator (Magnesium Green, Invitrogen) incor-
porating 0.2 mM EGTA to chelate free calcium. The Mg2+ level in
the media is 88 mM, much lower than concentrations of Mg2+ that
provide extensive blockade of NMDA receptors.
Neurons were aged 14–20 days after plating before being used
for iron uptake assays. Cells were treated as follows: 100 mM
NMDA for 30 min, 300 mM NMDA for 10 min, or 5 mM ionomycin for
10 min. For samples with MK801, cells were pretreated with 10 mM
MK801 for 10 min, then 100 mM NMDA was added for 30 min. Cells
were then washed once with warm PBS. For samples with MK801,
the drug was added back after NMDA treatment.
For NTBI uptake assays, 1 ml of warm Iron Uptake Buffer contain-
ing 20 mM iron prepared as above was added to each well and incu-
bated at 37C with 5% CO2 atmosphere in a humidified incubator for
30 min. Cells were harvested, washed twice in cold PBS plus 0.5 mM
EDTA, and processed as above.
For Tf-iron uptake pathway, assays were performed as previously
described (Kim and Ponka, 2002). In brief, apo-transferrin was
loaded with 55Fe2+ and the concentration measured. After treatment,
cells were incubated in a final concentration of 10 mM transferrin
(1 mM 55Fe-transferrin and 9 mM holo-transferrin) in 1 ml of Primary
Neuron Media for 2 hr. Cells were harvested, washed twice in cold
PBS plus 0.5 mM EDTA, and processed as above.RNA Interference in PC12 cells
The Dexras1 RNA interference (RNAi) insert was designed using the
Genescript siRNA design center and cloned into pRNAT-U6.1/Neo
(Genescript). To obtain knockdown in PC12 cells, 24 mg of Dexras1
RNAi were transfected into cells using Lipofectamine 2000 (Invitro-
gen) in Optimem overnight. Control transfection used the pRNAT-
U6.1/Neo empty vector. The next morning, cells were fed with full
media and allowed to recover for 24 hr. They were transfected again
overnight and then allowed to recover for 2 days before treatment
with GSNO for 3 hr. The transfection efficiency after the double
transfection was greater than 90%. To monitor knockdown, lysate
(100 mg) was run on a Western blot (mock-transfected cells had no
DNA), and Dexras1 protein levels were monitored using a rabbit
anti-Dexras1 antibody.
Heme Incorporation Assay
Primary rat cortical neurons were treated with 100 mM NMDA, then
incubated in 55Fe-transferrin as described above. Cells were
washed in PBS plus 0.5 mM EDTA, then resuspended in 1 ml of
0.2 N HCl. Using an aliquot of cell lysate, the protein concentration
of individual samples was determined using the Bio-Rad Protein As-
say. The resuspended cells were heated at 100C for 10 min, cooled
on ice, and then transferred to glass test tubes. 10% TCA (3 ml) was
added to each sample, vortexed, and incubated on ice for 15 min.
Protein precipitate was pelleted by centrifugation, and the pellet
was washed in 3 ml of 10% TCA and resuspended in 500 ml of 0.2
N HCl. Scintillation fluid was added and 55Fe2+ incorporated into
heme counted in a scintillation counter. Samples were normalized
to control.
Measurement of Reactive Oxygen Species
To measure highly reactive oxygen species (hROS), such as hy-
droxyl free radicals generated by the Fenton reaction, we employed
2-[6-(4’-hydroxy)phenoxy-3H-xanthen-3-on-9-yl]benzoic acid (HPF)
(Cell Technology, Inc, Mountain View, CA). This scarcely fluorescent
compound developed by T. Nagano (Setsukinai et al., 2003) binds
specifically to hydroxyl free radicals and less specifically to peroxy-
nitrate and converts to a highly fluorescent molecule.
Rat primary cortical neurons were prepared as above and aged for
14 days after plating. Measurement of hROS was conducted accord-
ing to the manufacturer’s protocol. Briefly, neurons were pretreated
with either 0 mM or 100 mM SIH for 3 hr in full media, which was then
removed, and the cells were washed once with Hanks Balanced Salt
Solution (HBSS). 5 mM HPF in HBSS was added to the cells and in-
cubated at 37C with 5% CO2 atmosphere in a humidified incubator
for 30 min. 0 mM or 300 mM NMDA was then added to the cells and
incubated for another 30 min. Cells were harvested in HBSS and
fluorescence was measured in a fluorimeter utilizing excitation
488 nm and emission 515 nm.
Measurement of NMDA-Induced Neurotoxicity
Rat primary cortical neurons were prepared as above and aged for
14 days after plating. Briefly, neurons were pretreated with either
water (vehicle), 10 mM MK801 or 100 mM SIH for 3 hr in full media,
which was then removed. The cells were then treated with 300 mM
NMDA for 10 min in full media, then replaced with full media and in-
cubated for 24 hr at 37C with 5% CO2 atmosphere in a humidified
incubator. Cells were washed with PBS and incubated in 1 mg/ml
propidium iodide for 10 min to stain for dead cells. The neurons
were then fixed in 4% paraformaldehyde in PBS and stained with
Hoechst stain to visualize total cells using an Olympus IX81 fluores-
cent microscope. Cell death was assessed by the ratio of propidium
iodide-stained cells to total cells and expressed as percent cell
survival.
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